FCM
ZYNE

Firestone Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Firestone Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$3K – 481
2021
Q3 		$3K Hold
500
– – ﹤0.01% 433
2021
Q2 		$3K Hold
500
– – ﹤0.01% 424
2021
Q1 		$2K Buy
+500
New +$2.27K ﹤0.01% 458

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Firestone Capital Management's ZYNE Position: Q4 2021 in Review

Firestone Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2021, closing a stake of 500 shares — an estimated $3K sold.

Firestone Capital Management first reported a position in ZYNE in Q1 2021 and held it in 3 quarters. The position peaked at $3K in Q3 2021. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2021.

  • Firestone Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
  • Firestone Capital Management sold 500 Zynerba Pharmaceuticals, Inc shares in Q4 2021, an estimated $3K.
  • Firestone Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2021 and held it in 3 quarters.
  • Firestone Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $3K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2021.

Based on Firestone Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.